| INTRODUCTION
Since its emergence in the 1990s, 1 Babesia gibsoni has become the most commonly diagnosed species of Babesia in dogs in the United
States of America and is now widely distributed across the country. 2 A&A has been recommended for B. gibsoni, and approximately 80% of treated dogs have clinical "cures" with reductions in parasitemia below the detection limit of sensitive molecular diagnostic assays. 3, 4 Mutations in B. gibsoni cytb genes confer resistance to atovaquone, resulting in treatment failures. 5, 6 These nonsynonymous mutations often result in a M128I or M128V change in the putative atovaquone binding site. Atovaquone resistant mutants have been identified in blood samples collected before and after treatment but are more often documented in dogs in which treatment with A&A failed. [6] [7] [8] This suggests selection for rare mutants during treatment, which has been documented in vitro. 5 In Asia, B. gibsoni strains with M128I mutations
Abbreviations: A&A, atovaquone and azithromycin combination therapy; WT, Wild type; cytb, cytochrome b; DNA, deoxyribonucleic acid; CDM, clindamycin, doxycycline and metronidazole combination therapy were detected in 3%-47% of the canine blood samples tested. 6, 7, 9 To the authors' knowledge, the prevalence of M128 mutations in B. gibsoni in the United States has not been reported. Therefore, the primary purpose of our study was to determine the prevalence of M128 mutations in B. gibsoni-infected dogs using blood samples submitted to a diagnostic laboratory in the United States of America. The secondary purpose was to describe the number of dogs that had WT cytb in initial and M128 mutants in follow-up blood specimens. 
| MATERIALS AND METHODS

| Samples
| STATISTICAL ANALYSIS
Prevalence was calculated using initial samples only as follows (number of B. gibsoni PCR+ dogs with M128 mutants / number of B. gibsoni
PCR+ dogs). A one-sided Fisher's exact test was used to determine
whether there was a difference in the proportion of mutant strains of B. gibsoni in dogs that only tested positive on follow-up samples that were completed <60 days after the initial positive test compared to those that had positive tests that were completed ≥60 days after the initial positive test (Statcalc, EpiInfo ver. 7.2.2.6). Differences were considered significant at P < .05. The incidence of new cytb mutants in dogs that tested positive for B. gibsoni which then had follow-up testing was calculated as follows: (number of new cytb mutants / number of B. gibsoni positive dogs with WT cytb in the initial sample that had follow-up testing). New cytb mutants were defined as cytb mutants that were detected in dogs that had only had WT cytb detected in our initial sample.
| RESULTS
Eight-thousand six-hundred forty-two samples (8642 samples/8174 dogs) were tested for the presence of Babesia species DNA, of which 211 were positive for B. gibsoni DNA and PCR negative for other Babesia spp. Sixteen samples were excluded because they were either not available for mutation testing or cytb genes could not be amplified. One additional sample was excluded because B. canis vogeli coinfection was detected during repeat testing. One hundred ninety-four B. gibsoni-infected samples from 174 dogs were included in the final analyses (Supporting Information Figure S1 ). These B. gibsoni-infected Samples submitted for retesting were also analyzed with respect to timing of subsequent positive testing relative to the initial PCR+ tests.
Of the 44 dogs that had repeat testing, 9 dogs only had positive followup tests <60 days from our initial positive, and 10 dogs had positive follow-up tests ≥60 days from our initial positive test. The proportion of dogs that had M128 mutations was higher in dogs that tested positive ≥60 days from the initial PCR+ test (6/10) compared to dogs that only tested positive <60 days from the initial PCR+ test (0/9) (P = .008).
| DISCUSSION
Our study reaffirms that B. gibsoni infections occur in dogs throughout
North America, and this infection is detected most commonly in American Staffordshire Terrier/American Pit Bull Terrier type dogs (71% of the infected dogs in our study). Our study also documents the presence of B. gibsoni organisms with M128 mutations that have been previously associated with resistance to atovaquone. Nearly half of these M128 mutants were detected in follow-up blood specimens from dogs initially infected with a WT cytb strain. Compared to other studies, the prevalence of M128 mutations in our samples (3.5%) were similar to the prevalence found in Japan (5%) and substantially lower than the prevalence found in Taiwan (47%) . 7, 9, 12 There are a number of potential reasons for the differences including study design/sample selection, frequency of atovaquone administration and geographic dif- commercially available. One such assay using an allele-specific SYBR-Green PCR was able to detect a rare M128 mutant (<1% of the population) in as many as 66% of the B. gibsoni samples tested. 9 The presence of these rare M128 mutants could explain treatment failures rates in Asia (20%-47%) that are substantially higher than apparent prevalence when DNA sequencing is used to define resistance. 14 
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